Pharmafile Logo

Considerations for Planning Effective and Appealing Advisory Boards: Importance of Participant Preferences

Explore our peer-reviewed article, “Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences.” Dive into key findings on HCPs’ preferences for virtual and hybrid meetings, revealing their desire for frequent interactions and the impactful use of their insights. Discover why virtual options are favored for their convenience, inclusivity, and lower environmental impact.

Pharmaceutical advisory boards and other small-group meetings with health care providers (HCPs) are important for getting feedback on new clinical trial results, competitors’ products, or educational campaigns. However, they are typically expensive and require participants to travel long distances and take time away from their work and families. For in-person meetings, there are also issues with not everyone being able to contribute as much as they want, and the exclusion of people living in remote or underserved communities is common.

These days, pharmaceutical companies have a choice between hosting meetings in person, virtually, or using a hybrid approach. In making this choice, the cost and organizer’s preference are usually key considerations, but very few people ask the participants what they prefer.

To help answer this question and elucidate the preferred meeting format, frequency, and follow-up approach, we conducted a short feedback survey among HCPs participating in virtual advisory boards in 2022 and 2023. The results were recently published in Pharmaceutical Medicine.

Key findings included that:

  • The majority of health care providers prefer virtual or hybrid pharmaceutical meetings/advisory boards over in-person-only meetings.
  • Health care providers prefer to meet at least 2–4 times per year and want to receive continuous updates on how the pharmaceutical company is using their insights.
  • Key benefits of virtual versus in-person meetings include their superior convenience and flexibility, low environmental impact, and the ability to hear from more diverse participants.

Access the full article here, titled Considerations for Planning Effective and Appealing Advisory Boards and Other Small-Group Meetings with Health Care Providers: Importance of Participant Preferences.

This content was provided by Impetus Digital

Company Details

 Latest Content from  Impetus Digital 

Navigating the Nuances of Europe’s MedTech Industry

Richard Houlihan, CEO of EirMed, explores topics related to EUDAMED, the European Databank for Medical Devices, including the key pain points and concerns MedTech companies encounter related to EUDAMED and...

Pharma, Technology, and Healthcare in the New Normal

Brian Canestraro, General Manager at Intercept Pharmaceuticals, discusses leadership lessons and tips to the impact of the COVID-19 pandemic on the way that Pharma conducts clinical trials and interacts with...

Traversing the Medtech Regulatory Landscape in the Interest of Patients

Dr. Bassil Akra, CEO of AKRA TEAM GmbH, takes a deep dive into the new approval process for medical devices in the EU and shares how his company is supporting...

Scanning for Health Indicators and Risks Through Your Smartphone

Vlado Bosanac, Co-Founder & Head of Strategy and Revenue Growth at Advanced Human Imaging, dives into the implications of increased integration of tech and data into daily life for the...

Virtual MSL/Sales training programs and events

Top 10 ways to leverage the Impetus InSite Platform® for internal MSL/Sales training programs and events

Top 10 Benefits of Virtual Advisory Boards

As the world is slowly starting to open up again, it can be tempting to rush back to the pre-pandemic days of in-person advisory boards. However, it would be foolish...

Amplifying Opinions of Patients & Caregivers for Higher Quality of Care

Pam Cusick, Senior Vice President of Rare Patient Voice, dives into diversity, equity, and inclusion in Pharma and clinical trials; ways to enhance the patient’s voice in their treatment journey...

The Future of MedTech: Streamlined Clinical Data Collection & Management

Jón Ingi Bergsteinsson, Co-founder & CCO at SMART-TRIAL, explores the barriers to, and benefits of, digitalization of clinical operations and trials in the MedTech industry, plus much more!

Digital Opinion Leaders (DOLs): Who are they and how can Pharma engage them?

With our growing dependence on social media, Digital Opinion Leaders are becoming an increasingly important stakeholder group for Pharma teams to engage and consult. But who are these DOLs, and...

Engaging Patients “Just-In-Time” with Machine Learning

Omri Shor, Co-founder & CEO of Medisafe, explores how Pharma companies can use digital therapeutics for advancing and supporting the patient journey, how new digital health tools are driving deeper...